The evolving role of oestrogen receptor beta in clinical breast cancer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Controversy surrounds the potential clinical importance of oestrogen receptor (ER)beta in breast cancer, and three recent papers have sought to resolve this. In the present issue of Breast Cancer Research Novelli and colleagues explored the significance of ERbeta1 expression in 936 breast cancer patients, and they showed diverse relationships according to lymph node status. A second paper examined 442 breast cancers in which ERbeta1 was an independent predictor of recurrence, disease-free survival and overall survival. Finally a third paper showed that ERbeta2 was a powerful prognostic indicator in 757 breast cancers but this was dependent on cellular location, with nuclear ERbeta2 expression predicting good survival whilst cytoplasmic expression predicted worse outcome. These papers point to a clinical role for ERbeta in breast cancer and shall be discussed.

Original languageEnglish
Pages (from-to)111
JournalBreast Cancer Research
Volume10
Issue number5
DOIs
Publication statusPublished - 2008

Fingerprint

Estrogen Receptor beta
Breast Neoplasms
Survival
Disease-Free Survival
Lymph Nodes
Recurrence
Research

Keywords

  • Adenocarcinoma
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Cell Nucleus
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Cytoplasm
  • Disease-Free Survival
  • Estrogen Receptor beta
  • Estrogens
  • Female
  • Humans
  • Lymphatic Metastasis
  • Neoplasm Proteins
  • Neoplasms, Hormone-Dependent
  • Prognosis
  • Survival Analysis
  • Comment
  • Editorial

Cite this

The evolving role of oestrogen receptor beta in clinical breast cancer. / Speirs, Valerie.

In: Breast Cancer Research, Vol. 10, No. 5, 2008, p. 111.

Research output: Contribution to journalArticle

@article{68af8c67d49a419da9291cec744e45fb,
title = "The evolving role of oestrogen receptor beta in clinical breast cancer",
abstract = "Controversy surrounds the potential clinical importance of oestrogen receptor (ER)beta in breast cancer, and three recent papers have sought to resolve this. In the present issue of Breast Cancer Research Novelli and colleagues explored the significance of ERbeta1 expression in 936 breast cancer patients, and they showed diverse relationships according to lymph node status. A second paper examined 442 breast cancers in which ERbeta1 was an independent predictor of recurrence, disease-free survival and overall survival. Finally a third paper showed that ERbeta2 was a powerful prognostic indicator in 757 breast cancers but this was dependent on cellular location, with nuclear ERbeta2 expression predicting good survival whilst cytoplasmic expression predicted worse outcome. These papers point to a clinical role for ERbeta in breast cancer and shall be discussed.",
keywords = "Adenocarcinoma, Antineoplastic Agents, Hormonal, Breast Neoplasms, Cell Nucleus, Chemotherapy, Adjuvant, Cohort Studies, Cytoplasm, Disease-Free Survival, Estrogen Receptor beta, Estrogens, Female, Humans, Lymphatic Metastasis, Neoplasm Proteins, Neoplasms, Hormone-Dependent, Prognosis, Survival Analysis, Comment, Editorial",
author = "Valerie Speirs",
year = "2008",
doi = "10.1186/bcr2140",
language = "English",
volume = "10",
pages = "111",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "5",

}

TY - JOUR

T1 - The evolving role of oestrogen receptor beta in clinical breast cancer

AU - Speirs, Valerie

PY - 2008

Y1 - 2008

N2 - Controversy surrounds the potential clinical importance of oestrogen receptor (ER)beta in breast cancer, and three recent papers have sought to resolve this. In the present issue of Breast Cancer Research Novelli and colleagues explored the significance of ERbeta1 expression in 936 breast cancer patients, and they showed diverse relationships according to lymph node status. A second paper examined 442 breast cancers in which ERbeta1 was an independent predictor of recurrence, disease-free survival and overall survival. Finally a third paper showed that ERbeta2 was a powerful prognostic indicator in 757 breast cancers but this was dependent on cellular location, with nuclear ERbeta2 expression predicting good survival whilst cytoplasmic expression predicted worse outcome. These papers point to a clinical role for ERbeta in breast cancer and shall be discussed.

AB - Controversy surrounds the potential clinical importance of oestrogen receptor (ER)beta in breast cancer, and three recent papers have sought to resolve this. In the present issue of Breast Cancer Research Novelli and colleagues explored the significance of ERbeta1 expression in 936 breast cancer patients, and they showed diverse relationships according to lymph node status. A second paper examined 442 breast cancers in which ERbeta1 was an independent predictor of recurrence, disease-free survival and overall survival. Finally a third paper showed that ERbeta2 was a powerful prognostic indicator in 757 breast cancers but this was dependent on cellular location, with nuclear ERbeta2 expression predicting good survival whilst cytoplasmic expression predicted worse outcome. These papers point to a clinical role for ERbeta in breast cancer and shall be discussed.

KW - Adenocarcinoma

KW - Antineoplastic Agents, Hormonal

KW - Breast Neoplasms

KW - Cell Nucleus

KW - Chemotherapy, Adjuvant

KW - Cohort Studies

KW - Cytoplasm

KW - Disease-Free Survival

KW - Estrogen Receptor beta

KW - Estrogens

KW - Female

KW - Humans

KW - Lymphatic Metastasis

KW - Neoplasm Proteins

KW - Neoplasms, Hormone-Dependent

KW - Prognosis

KW - Survival Analysis

KW - Comment

KW - Editorial

U2 - 10.1186/bcr2140

DO - 10.1186/bcr2140

M3 - Article

C2 - 18831727

VL - 10

SP - 111

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 5

ER -